Table 2.

Partial listing of ongoing clinical trials evaluating immunotherapy and cytotoxic therapy for newly diagnosed glioblastoma

Immunotherapy/Agent	Phase	# Patients	Accrual Status	Clinicaltrials.gov	Comment
EGFRvIII peptide vaccine/Rindopepimut	3	700	Completed	NCT01480479	Randomized; double-blind; placebo-controlled;
Tumor lysate loaded DCs/DCVax®-L	3	300	Ongoing	NCT00045968	Randomized; double-blind; placebo-controlled;
Tumor lysate-loaded DCs	2	100	Ongoing	NCT01567202	Randomized; double-blind; placebo-controlled;
Tumor-associated antigen vaccine/ICT107	2	124	Completed	NCT01280552	Randomized; double-blind; placebo-controlled
Tumor-associated antigen vaccine/IMA950	1/2	16	Ongoing	NCT01920191	IMA950
Autologous and allogeneic tumor-specific neoantigens/APVAC	1	30	Ongoing	NCT02149225
Autologous tumor-specific neoantigens/NeoVax	1	16	Ongoing	NCT02287428	MGMT-unmethylated patients only; excludes temozolomide
Autologous DCs + allogeneic stem cell lysate	1	40	Ongoing	NCT02010606
Autologous DCs + allogeneic stem cell lysate	1	10	Ongoing	NCT01957956
Autologous DCs loaded with CMV pp65-LAMP RNA	1	16	Ongoing	NCT00639639
Autologous DCs loaded with CMV pp65-LAMP RNA + basliximab	1	18	Ongoing	NCT00626483
PD-L1 mAb/MEDI4736	2	37	Ongoing	NCT02336165	MGMT-unmethylated patients only; excludes temozolomide